Jedd D Wolchok
Overview
Explore the profile of Jedd D Wolchok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
434
Citations
88887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Widman A, Shah M, Frydendahl A, Halmos D, Khamnei C, Ogaard N, et al.
Nat Med
. 2024 Jun;
30(6):1655-1666.
PMID: 38877116
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of...
12.
Smithy J, Kalvin H, Ehrich F, Shah R, Adamow M, Raber V, et al.
Clin Cancer Res
. 2024 May;
30(16):3407-3415.
PMID: 38767650
Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker...
13.
Kraehenbuehl L, Wolchok J, Merghoub T, Hirschhorn D
Cancer Cell
. 2024 Apr;
42(5):738-741.
PMID: 38579723
Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening...
14.
Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N, et al.
Nat Cancer
. 2024 Mar;
5(5):760-773.
PMID: 38503896
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve comparable outcomes. Importantly, chimeric antigen receptors...
15.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, von Bergwelt-Baildon M, et al.
Eur J Cancer
. 2024 Jan;
199:113505.
PMID: 38262306
Background: Immunotherapies such as immune checkpoint inhibitors (ICI) are effective in multiple tumor entities but induce a plethora of side effects. Comprehensive real-world analyses are essential to identify new signals,...
16.
Chapman P, Klang M, Postow M, Shoushtari A, Sullivan R, Wolchok J, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2447-2454.
PMID: 37930123
Purpose: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma. We conducted a phase Ib dose-escalation trial...
17.
Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George M, et al.
Life Sci Alliance
. 2023 Oct;
7(1).
PMID: 37891002
We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ)...
18.
Topp B, Channavazzala M, Mayawala K, De Alwis D, Rubin E, Snyder A, et al.
Cancer Cell
. 2023 Sep;
41(9):1680-1688.e2.
PMID: 37699333
While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified. Data from 799 patients with melanoma (n ...
19.
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, et al.
Cancer Cell
. 2023 Jun;
41(7):1363-1380.e7.
PMID: 37327788
Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying mechanisms remain unelucidated. We find that LKB1 loss results in enhanced...
20.
Rojas L, Sethna Z, Soares K, Olcese C, Pang N, Patterson E, et al.
Nature
. 2023 May;
618(7963):144-150.
PMID: 37165196
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines . Here in a phase I trial of adjuvant...